Icaritin

Phase 3Small molecule

BBeijing Shenogen Biomedical Co., Ltd

Icaritin is one of 77 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular CarcinomaTerminated

Pancreatic Ductal AdenocarcinomaRecruiting

Hepatocellular CarcinomaPhase 3

Terminated

Pancreatic Ductal AdenocarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

265 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Icaritin

BBeijing Shenogen Biomedical Co., Ltd

Phase 3

5 2

Cysteine Hydrochloride

Novartis

Preclinical

1 3

Ibrance

Pfizer

Preclinical

1 4

Viread

Gilead

Preclinical

1 5

Sovaldi

Gilead

Preclinical

1 6

Hepsera

Coreg

2 8

Vermox

WWim Janssens

Preclinical

1 9

Doptelet

AAkarx

Preclinical

1 10

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Pancreatic Ductal Adenocarcinoma

NCT06825546

Q1 2028

N/ARecruiting

Hepatocellular Carcinoma

NCT06893887

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma5 trials

The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma

Completed·BBeijing Shenogen Biomedical Co., Ltd·Phase 2·NCT01972672·70 enrolled

The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

Terminated·BBeijing Shenogen Biomedical Co., Ltd·Phase 3·NCT03236649·89 enrolled

Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)

Recruiting·BBeijing Shenogen Biomedical Co., Ltd·Phase 3·NCT05594927·261 enrolled

Show 2 more trials

The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects

Unknown status·BBeijing Shenogen Biomedical Co., Ltd·Phase 3·NCT03236636·312 enrolled

Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma

Recruiting·NNanjing Tianyinshan Hospital·N/A·NCT06893887·300 enrolled

Breast Cancer1 trial

Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients

Unknown status·CChinese Academy of Medical Sciences·Phase 1·NCT01278810·30 enrolled

First-line Treatment1 trial

Tace With Icaritin in First-line Treatment of Middle and Advanced HCC in Child Grade B Patients

Unknown status·HHenan Cancer Hospital·Phase 2·NCT06285149·80 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma

Recruiting·SSir Run Run Shaw Hospital·Phase 2·NCT06825546·70 enrolled

Advanced Solid Tumors1 trial

A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors

Completed·CChinese Academy of Medical Sciences·Phase 1·NCT02496949·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Icaritin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Icaritin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Icaritin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Shenogen Biomedical Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBeijing Shenogen Biomedical Co., Ltd

Icaritin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2028

Trials by Indication[1]

Hepatocellular Carcinoma5 trials

Breast Cancer1 trial

First-line Treatment1 trial

Pancreatic Ductal Adenocarcinoma1 trial

Advanced Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News